GL1X · GenesisL1 explorer

Research workbench

Xray structure of human furin bound with the 2,5-dideoxystreptamine derived small molecule inhibitor 1N

Analyse Xray structure of human furin bound with the 2,5-dideoxystreptamine derived… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5MIM
Type
protein
Length
473 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Furin
EC
3.4.21.75
UniProt
P09958
Ligands
1N, NA, CA, CL
Pockets
4 · best druggability 0.46

Structure

x-ray diffraction · 1 distinct chain · 20% helix, 27% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AFurin (EC 3.4.21.75)protein47320% helix, 27% strandP09958

Ligands and binding sites

  • 1N · 1-[(1~{R},2~{R},4~{S},5~{S})-2,4-bis(4-carbamimidamidophenoxy)-5-[(4-carbamimidamidophenyl) amino]cyclohexyl]guanidine · ligand · 2 copies · chains A
  • NA · Sodium ion · metal · 4 copies · chains A
  • CA · Calcium ion · metal · 3 copies · chains A
  • CL · Chloride ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11210.460.7814empty
2840.340.7520empty
3550.320.7715empty
4620.270.7323empty

Modifications

Observed in the structure: 3 disulfide (disulfide).

Compared structures

  • 5MIM · Xray structure of human furin bound with the 2,5-dideoxystreptamine derived small… · the same entry in another collection · chain A against A, TM-score 1.00
  • P09958 · AlphaFold monomer V2.0 prediction for furin (P09958) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.